Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
13:00:53 EDT Sun 05 May 2024
Enter Symbol
or Name
USA
CA



News for U:ABBV from 2023-05-04 to 2024-05-03 - 101 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-26 07:35U:ABBVNews ReleaseAbbVie Reports First-Quarter 2024 Financial Results
2024-04-25 08:00U:ABBVNews ReleaseNew Data Show RINVOQ(TM) (upadacitinib) Demonstrated Superiority Versus DUPIXENT(TM) (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study
2024-04-23 08:00U:ABBVNews ReleaseAllergan Aesthetics Invites Consumers to Be the Face of BOTOX(TM) Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands
2024-04-18 08:31U:ABBVNews ReleasePhase 3 SELECT-GCA Study of Upadacitinib (RINVOQ(TM)) Showed Positive Results in Patients With Giant Cell Arteritis
2024-04-12 07:30U:ABBVNews ReleaseAbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA(TM)) for Preventive Treatment of Migraine
2024-04-09 08:00U:ABBVNews ReleaseSkinMedica(TM) Empowers Clear Skin Confidence with a New, Modern Approach to Acne
2024-04-04 08:00U:ABBVNews ReleaseAbbVie to Host First-Quarter 2024 Earnings Conference Call
2024-04-03 08:30U:ABBVNews ReleaseAllergan Aesthetics Announces the Return of CoolMonth with CoolSculpting(TM)
2024-04-01 07:50U:ABBVNews ReleaseNEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year
2024-03-25 11:00U:ABBVNews ReleaseAllergan Aesthetics Launches "Moving the Needle on Ethics" to Elevate the Conversation Around Ethics in Aesthetics
2024-03-25 08:31U:ABBVNews ReleaseAbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
2024-03-25 08:30U:ABBVNews ReleaseAbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
2024-03-22 15:02U:ABBVNews ReleaseU.S. Food and Drug Administration (FDA) Grants Full Approval for ELAHERE(TM) (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients
2024-03-21 08:00U:ABBVNews ReleaseALLERGAN AESTHETICS CONTINUES TO CHAMPION INDIVIDUALITY, DRIVE INNOVATION AND LEAD WITH INTEGRITY AS IT HOSTS EXPERT LED SYMPOSIA AT AMWC 2024
2024-03-07 08:00U:ABBVNews ReleaseAbbVie to Present at the Barclays 26th Annual Global Healthcare Conference
2024-03-06 08:03U:ABBVNews ReleaseAbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics Portfolios
2024-03-05 08:30U:ABBVNews ReleaseIncreasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
2024-03-05 08:00U:ABBVNews ReleaseJUVEDERM(TM) VOLUMA(TM) XC For Temple Hollows Receives U.S. FDA Approval
2024-03-05 07:00U:ABBVNews ReleaseDragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303
2024-03-05 07:00U:ABBVNews ReleaseDragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303
2024-02-28 00:05U:ABBVNews ReleaseAbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation
2024-02-27 08:00U:ABBVNews ReleaseAbbVie to Present at the TD Cowen 44th Annual Health Care Conference
2024-02-27 08:00U:ABBVNews ReleaseHealis Therapeutics' asset CKDB-501A shares Phase III topline results for glabellar injections from CKD Bio in South Korea
2024-02-27 07:45U:ABBVNews ReleaseU.S. Food and Drug Administration (FDA) Grants Priority Review of Epcoritamab (EPKINLY(TM)) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma (FL)
2024-02-22 08:05U:ABBVNews ReleaseAbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology
2024-02-21 08:00U:ABBVNews ReleaseBOTOX ‚ ® Cosmetic (onabotulinumtoxinA) Announces Its 2024 Grant Program Supporting Women Entrepreneurs
2024-02-20 09:00U:ABBVNews ReleaseAbbVie Announces Appointment of Robert A. Michael as Chief Executive Officer
2024-02-19 08:30U:ABBVNews ReleaseAbbVie Unveils New Data from Robust Gastroenterology Portfolio at the 19th Congress of European Crohn's and Colitis Organisation (ECCO)
2024-02-15 12:03U:ABBVNews ReleaseAbbVie Declares Quarterly Dividend
2024-02-15 08:45U:ABBVNews ReleaseGlobal Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
2024-02-12 07:37U:ABBVNews ReleaseAbbVie Completes Acquisition of ImmunoGen
2024-02-06 12:00U:ABBVNews ReleaseCalibr-Skaggs announces expansion of option and license agreement with AbbVie to develop novel cell therapies for solid tumors and autoimmune diseases
2024-02-02 07:36U:ABBVNews ReleaseAbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
2024-01-31 11:00U:ABBVNews ReleaseAllergan Aesthetics Releases "Decoding the Future of Aesthetic Individuality" Exploring the Power of Self-Expression
2024-01-25 03:00U:ABBVNews ReleaseAllergan Aesthetics Showcases Commitment to Individuality, Innovation, and Integrity at IMCAS World Congress 2024
2024-01-23 08:00U:ABBVNews ReleaseAll „ “ by Allergan Aesthetics is the Leading Aesthetics Loyalty Rewards Program in the U.S.
2024-01-09 02:00U:ABBVNews ReleaseAbbVie Launches PRODUODOPA ‚ ® (foslevodopa/foscarbidopa) for People Living with Advanced Parkinson's Disease in the European Union
2024-01-08 08:05U:ABBVNews ReleaseLutikizumab Showed Positive Results in a Phase 2 Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase 3
2024-01-04 08:45U:ABBVNews ReleaseAbbVie and Umoja Biopharma Announce Strategic Collaboration to Develop Novel In-Situ CAR-T Cell Therapies
2024-01-04 08:00U:ABBVNews ReleaseAbbVie to Host Full-Year and Fourth-Quarter 2023 Earnings Conference Call
2024-01-02 08:00U:ABBVNews ReleaseAbbVie to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-09 12:00U:ABBVNews ReleaseNew Data for Bispecific Antibody Epcoritamab (DuoBody ‚ ® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
2023-12-06 16:30U:ABBVNews ReleaseAbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
2023-12-05 08:45U:ABBVNews ReleaseAbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies
2023-11-30 13:46U:ABBVNews ReleaseINVESTOR ALERT: Weiss Law Investigates ImmunoGen, Inc.
2023-11-30 07:30U:ABBVNews ReleaseAbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE ‚ ® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
2023-11-29 08:45U:ABBVNews ReleaseAbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC)
2023-11-27 07:00U:ABBVNews ReleaseAbbVie Announces U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Updates for Epcoritamab (EPKINLY ‚ ®/TEPKINLY ‚ ®) for the Treatment of Relapsed/Refractory Follicular Lymphoma
2023-11-20 08:45U:ABBVNews ReleaseFifth Annual BOTOX ‚ ® Cosmetic (onabotulinumtoxinA) Day Makes History as the Biggest Day Ever
2023-11-16 07:00U:ABBVNews ReleaseResults Published in The Lancet Show UBRELVY ‚ ® (ubrogepant) Reduces the Headache Phase of a Migraine Attack When Dosed During the Prodrome of Migraine
2023-11-13 16:05U:ABBVNews ReleaseNEXGEL Reports Record Third Quarter 2023 Revenue of $1.2 Million, an Increase of 115% Year-Over-Year
2023-11-08 08:45U:ABBVNews ReleaseNatrelle ‚ ® Unveils New "For Every BODY" Campaign
2023-11-02 08:31U:ABBVNews ReleaseRoundhill Investments Launches Dividend Monarchs ETF (NYSE Arca: KNGS)
2023-11-01 08:45U:ABBVNews ReleaseBOTOX ‚ ® Cosmetic (onabotulinumtoxinA) Day is Back Like Never Before
2023-10-30 08:00U:ABBVNews ReleaseNEXGEL Secures Supply Agreement with AbbVie
2023-10-27 07:38U:ABBVNews ReleaseAbbVie Reports Third-Quarter 2023 Financial Results
2023-10-24 08:30U:ABBVNews ReleaseAllergan Aesthetics Announces Positive Topline Results from Two Pivotal Phase 3 Studies of TrenibotulinumtoxinE (BoNT/E) for the Treatment of Glabellar Lines
2023-10-19 08:45U:ABBVNews ReleaseAllergan Aesthetics Supports Breast Cancer Patients and Celebrates Breast Reconstruction Patients Through The Reblossom Project
2023-10-15 11:15U:ABBVNews ReleaseAbbVie's SKYRIZI ‚ ® (risankizumab) Versus STELARA ‚ ® (ustekinumab) Head-to-Head Study in Crohn's Disease Meets All Primary and Secondary Endpoints
2023-10-12 05:25U:ABBVNews ReleaseAbbVie Announces Upadacitinib (RINVOQ ‚ ®) Met the Primary Endpoint in Phase 2 Clinical Trial of Vitiligo as Program Advances to Phase 3
2023-10-11 08:30U:ABBVNews ReleaseAbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ (upadacitinib) in Adults and Adolescents with Moderate to Severe Atopic Dermatitis
2023-10-10 08:45U:ABBVNews ReleaseAbbVie Showcases Breadth and Depth of Research in Crohn's Disease and Ulcerative Colitis at UEG Week 2023
2023-10-05 08:05U:ABBVNews ReleaseAbbVie Exercises Exclusive Right to Acquire Mitokinin, Further Strengthening Neuroscience Pipeline
2023-10-04 11:07U:ABBVNews ReleaseNature Publishes Discovery and Preclinical Results for ABBV-CLS-484, a Potential First-in-Class PTPN2/N1 Inhibitor in Cancer Immunotherapy
2023-10-04 08:00U:ABBVNews ReleaseAbbVie to Host Third-Quarter 2023 Earnings Conference Call
2023-10-03 07:00U:ABBVNews ReleaseAllergan Aesthetics and Girls Inc. Partner to Speed the Entry of Young Women into Positions of Leadership in the STEM Field
2023-09-29 07:15U:ABBVNews ReleaseAbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma
2023-09-25 07:45U:ABBVNews ReleaseAbbVie Announces European Commission Approval of TEPKINLY ‚ ® (epcoritamab) for Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma
2023-09-18 09:00U:ABBVNews ReleaseAllergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of OnabotulinumtoxinA (BOTOX ‚ ® Cosmetic) for the Treatment of Platysma Prominence
2023-09-13 11:00U:ABBVNews ReleaseAbbVie Calls on Public to Vote for the 2023 AbbVie Cystic Fibrosis Scholarship "Thriving Students"
2023-09-12 08:30U:ABBVNews ReleaseAbbVie's SKYRIZI ‚ ® (risankizumab) Met All Primary and Secondary Endpoints Versus Stelara ‚ ® (ustekinumab) in Head-to-Head Study in Crohn's Disease
2023-09-08 11:23U:ABBVNews ReleaseAbbVie Declares Quarterly Dividend
2023-09-07 07:00U:ABBVNews ReleaseAlector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimer ¢ € ™s Disease
2023-09-06 08:45U:ABBVNews ReleaseJoin BOTOX ‚ ® Cosmetic (onabotulinumtoxinA) and IFundWomen in Supporting Women Entrepreneurs
2023-09-06 08:00U:ABBVNews ReleaseAbbVie to Present at the Morgan Stanley Healthcare Conference
2023-08-30 09:00U:ABBVNews ReleaseJournal of Cosmetic Dermatology Publishes Data Demonstrating Patient Satisfaction with Natural-Looking Outcomes Following Treatment with OnabotulinumtoxinA (BOTOX ‚ ® Cosmetic)
2023-08-28 08:45U:ABBVNews ReleaseAbbVie Submits Regulatory Applications to FDA and EMA for Risankizumab (SKYRIZI ‚ ®) in Ulcerative Colitis
2023-08-17 02:00U:ABBVNews ReleaseAbbVie Announces European Commission Approval of AQUIPTA ‚ ® (atogepant) for the Preventive Treatment of Migraine in Adults
2023-08-01 08:45U:ABBVNews ReleaseAllergan Aesthetics Announces First Ever JUV ƒ ‰DERM ‚ ® Day
2023-07-27 07:38U:ABBVNews ReleaseAbbVie Reports Second-Quarter 2023 Financial Results
2023-07-26 09:00U:ABBVNews ReleaseAbbVie and Calibr Expand Strategic Collaboration to Advance Several Preclinical and Early-stage Clinical Assets
2023-07-26 08:05U:ABBVNews ReleaseSKYRIZI ‚ ® (risankizumab) Achieved Superiority Versus Apremilast for Co-Primary Endpoints Among Adult Patients with Moderate Plaque Psoriasis in Phase 4 Head-to-Head Study
2023-07-24 08:05U:ABBVNews ReleaseAbbVie Advances Immunology Pipeline with First Patient Dosed in Global Phase 3 Trial of Upadacitinib (RINVOQ ‚ ®) in Hidradenitis Suppurativa
2023-07-21 04:30U:ABBVNews ReleaseAbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY ‚ ®) for the Treatment of Adults with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
2023-07-06 08:00U:ABBVNews ReleaseAbbVie to Host Second-Quarter 2023 Earnings Conference Call
2023-06-28 06:30U:ABBVNews ReleaseKineta Expands Board of Directors with Biotech Industry Leaders Kim Drapkin and Scott Dylla
2023-06-27 18:50U:ABBVNews ReleaseAbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE ¢ „ ¢ NHL-1 Trial Evaluating Epcoritamab (DuoBody ‚ ®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
2023-06-26 08:00U:ABBVNews ReleaseAbbVie Employees Volunteer During 8th Annual "Week of Possibilities" to Support Communities Globally
2023-06-23 08:04U:ABBVNews ReleaseAbbVie Secures Positive CHMP Opinion for Atogepant for the Preventive Treatment of Adults with Migraine
2023-06-22 13:13U:ABBVNews ReleaseAbbVie Declares Quarterly Dividend
2023-06-15 08:45U:ABBVNews ReleaseRisankizumab (SKYRIZI ‚ ®) Met Primary and Key Secondary Endpoints in 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients
2023-06-13 08:45U:ABBVNews ReleaseBOTOX ‚ ® Cosmetic (onabotulinumtoxinA) Announces the Winners of the IFundWomen Grant Program
2023-06-09 03:00U:ABBVNews ReleaseAbbVie's VENCLYXTO ‚ ®/VENCLEXTA ‚ ® (venetoclax) Continues to Show Sustained Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) Patients
2023-06-06 08:00U:ABBVNews ReleaseAbbVie to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
2023-05-31 02:30U:ABBVNews ReleasePhase 2 Study of Upadacitinib (RINVOQ ‚ ®) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus
2023-05-25 08:45U:ABBVNews ReleaseNew England Journal of Medicine Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ ‚ ®) in Crohn's Disease
2023-05-24 09:00U:ABBVNews ReleaseAbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ ‚ ® (upadacitinib) Across Multiple Rheumatic Diseases at the EULAR 2023 Congress
2023-05-19 12:34U:ABBVNews ReleaseEPKINLY ¢ „ ¢ (epcoritamab-bysp) Approved by U.S. FDA as the First and Only Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
2023-05-18 12:25U:ABBVNews ReleaseU.S. FDA Approves RINVOQ ‚ ® (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults
2023-05-15 08:45U:ABBVNews ReleaseSKINVIVE ¢ „ ¢ by JUV ƒ ‰DERM ‚ ® Receives U.S. FDA Approval
2023-05-06 07:30U:ABBVNews ReleaseAbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week ‚ ®